Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrotalcite for Hyperphosphatemia in Hemodialysis
ChiCTR-IPR-16007785Phase 4Not yet recruiting
- Sponsor
- Xiamen University Affiliated Zhongshan Hospital
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of hydrotalcite in chronic kidney disease (CKD) and hyperphosphatemia (2 arms), sponsored by Xiamen University Affiliated Zhongshan Hospital. Primary endpoints: Serum phosphorus and Serum aluminium. Planned start Jan 2016; status: not yet recruiting.
02
Drugs
hydrotalcite
03
Conditions
chronic kidney disease (CKD)hyperphosphatemia
Beyond the preview
Go deeper on ChiCTR-IPR-16007785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16007785.